EX-99.2 3 a2022q4exhibit992.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FOURTH QUARTER
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$12,516  12,163  2.9 % 2.9 — 
Europe 5,816  6,925 (16.0) (6.3) (9.7)
Western Hemisphere excluding U.S. 1,545  1,459  5.9  11.8  (5.9)
Asia-Pacific, Africa 3,829  4,257  (10.0) 3.1  (13.1)
International 11,190  12,641  (11.5) (1.1) (10.4)
      
Worldwide$23,706  24,804  (4.4)% 0.9  (5.3)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
TWELVE MONTHS
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$48,580  47,156  3.0 % 3.0 — 
Europe 23,449  23,594  (0.6) 11.0  (11.6)
Western Hemisphere excluding U.S. 6,125  5,750  6.5  10.2  (3.7)
Asia-Pacific, Africa 16,789  17,275  (2.8) 6.2  (9.0)
International 46,363  46,619  (0.6) 9.1  (9.7)
      
Worldwide$94,943  93,775  1.3 % 6.1  (4.8)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$1,696 1,529 10.9 %10.9 — 
    International2,071 2,199 (5.8)3.2 (9.0)
3,767    3,728 1.0 6.4 (5.4)
Pharmaceutical (1)
    U.S.7,375 7,418 (0.6)(0.6)— 
    International5,788 6,799 (14.9)(4.5)(10.4)
13,163    14,217 (7.4)(2.5)(4.9)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.7,375 7,205 2.4 2.4— 
     International5,099 5,394 (5.5)6.0(11.5)
12,474 12,599 (1.0)3.9(4.9)
MedTech (2)
    U.S.3,445    3,216 7.1 7.1 — 
    International3,331 3,643 (8.6)2.9 (11.5)
 6,776    6,859 (1.2)4.9 (6.1)
U.S.12,516 12,163 2.9 2.9 — 
International11,190 12,641 (11.5)(1.1)(10.4)
Worldwide23,706 24,804 (4.4)0.9 (5.3)
   
U.S.12,516 11,950 4.7 4.7 — 
International10,501 11,236 (6.5)4.4 (10.9)
Worldwide excluding COVID-19 Vaccine (3)
$23,017 23,186 (0.7)%4.6 (5.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule.




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$6,599 6,516 1.3 %1.3 — 
    International8,354 8,519 (1.9)5.3 (7.2)
14,953    15,035 (0.5)3.6 (4.1)
Pharmaceutical (1)
    U.S.28,604 27,954 2.3 2.3 — 
    International23,959 23,726 1.0 11.9 (10.9)
52,563    51,680 1.7 6.7 (5.0)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.28,484 27,320 4.3 4.3— 
     International21,900 21,975 (0.3)10.3(10.6)
50,384 49,295 2.2 6.9(4.7)
MedTech (2)
    U.S.13,377    12,686 5.4 5.4 — 
    International14,050 14,374 (2.3)6.9 (9.2)
 27,427    27,060 1.4 6.2 (4.8)
U.S.48,580 47,156 3.0 3.0 — 
International46,363 46,619 (0.6)9.1 (9.7)
Worldwide94,943 93,775 1.3 6.1 (4.8)
   
U.S.48,460 46,522 4.2 4.2 — 
International44,304 44,868 (1.3)8.2 (9.5)
Worldwide excluding COVID-19 Vaccine (3)
$92,764 91,390 1.5 %6.2 (4.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule.


Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$23,706 100.0$24,804 100.0(4.4)
Cost of products sold7,765 32.87,955 32.1(2.4)
Gross Profit15,941 67.216,849 67.9(5.4)
Selling, marketing and administrative expenses6,512 27.47,154 28.9(9.0)
Research and development expense3,841 16.24,720 19.0(18.6)
In-process research and development173 0.7 00.0
Interest (income) expense, net(77)(0.3)47 0.2
Other (income) expense, net1,207 5.1 9 0.0
Restructuring84 0.483 0.3
Earnings before provision for taxes on income4,201 17.74,836 19.5(13.1)
Provision for taxes on income681 2.9100 0.4 581.0 
Net earnings$3,520 14.8$4,736 19.1(25.7)
Net earnings per share (Diluted)$1.33 $1.77 (24.9)
Average shares outstanding (Diluted)2,650.1 2,670.2 
Effective tax rate16.2 %2.1 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$7,418 31.3$6,339 25.617.0 
Net earnings$6,218 26.2$5,678 22.99.5 
Net earnings per share (Diluted)$2.35 $2.13 10.3 
Effective tax rate16.2 %10.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
TWELVE MONTHS
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$94,943 100.0$93,775 100.01.3 
Cost of products sold31,089 32.729,855 31.84.1 
Gross Profit63,854 67.363,920 68.2(0.1)
Selling, marketing and administrative expenses24,765 26.124,659 26.30.4 
Research and development expense14,603 15.414,714 15.7(0.8)
In-process research and development7830.8900 1.0  
Interest (income) expense, net(214)(0.2)130 0.1 
Other (income) expense, net1,871 2.0 489 0.5  
Restructuring321 0.3252 0.3
Earnings before provision for taxes on income21,725 22.922,776 24.3(4.6)
Provision for taxes on income3,784 4.01,898 2.0 99.4 
Net earnings$17,941 18.9$20,878 22.3(14.1)
Net earnings per share (Diluted)$6.73 $7.81 (13.8)
Average shares outstanding (Diluted)2,663.9 2,674.0 
Effective tax rate17.4 %8.3 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$31,880 33.6$30,464 32.54.6 
Net earnings$27,038 28.5$26,195 27.93.2 
Net earnings per share (Diluted)$10.15 $9.80 3.6 
Effective tax rate15.2 %14.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Fourth Quarter
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$3,520$4,736
Pre-tax Adjustments
Intangible Asset Amortization expense1,061 1,121
Litigation related262 274
IPR&D 173  -
Restructuring related140 140
Acquisition, integration and divestiture related ¹ 196 26
(Gains)/losses on securities 6 (198)
Medical Device Regulation 2
88  73
COVID-19 Vaccine related costs 3
821 -
Consumer Health separation costs470  67
Tax Adjustments
Tax impact on special item adjustments 4
(507)(184)
Consumer Health separation tax related costs35  -
Tax legislation and other tax related(47) (377)
Adjusted Net Earnings, after tax$6,218 $5,678 
Average shares outstanding (Diluted)2,650.1 2,670.2 
Adjusted net earnings per share (Diluted)$2.35 $2.13 
Operational adjusted net earnings per share (Diluted)$2.46  
Notes:
1
Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
3
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual requirements.
4
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Twelve Months Ended
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$17,941$20,878
Pre-tax Adjustments
Intangible Asset Amortization expense4,305 4,697
Litigation related866 2,328
IPR&D 783  900
Restructuring related463 473
Acquisition, integration and divestiture related 1
 196 (478)
(Gains)/losses on securities 690 (533)
Medical Device Regulation 2
296  234
COVID-19 Vaccine related costs 3
1,474  -
Consumer Health separation costs1,089  67
Other(7) -
Tax Adjustments
Tax impact on special item adjustments 4
(1,592)(1,281)
Consumer Health separation tax related costs494  -
Tax legislation and other tax related40  (1,090)
Adjusted Net Earnings, after tax$27,038$26,195
Average shares outstanding (Diluted)2,663.9 2,674.0 
Adjusted net earnings per share (Diluted)$10.15 $9.80 
Operational adjusted net earnings per share (Diluted)$10.70  
Notes:
1
Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition. Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
3
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual requirements.
4
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 FOURTH QUARTER 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical  MedTech  Total
 WW As Reported 1.0 %(7.4)%(1.2)%(4.4)%
 U.S. 10.9 %(0.6)%7.1 %2.9 %
 International (5.8)%(14.9)%(8.6)%(11.5)%
 WW Currency (5.4)(4.9)(6.1)(5.3)
 U.S. ————
 International (9.0)(10.4)(11.5)(10.4)
 WW Operational 6.4 %(2.5)%4.9 %0.9 %
 U.S. 10.9 %(0.6)%7.1 %2.9 %
International3.2 %(4.5)%2.9 %(1.1)%
Interventional Solutions
Abiomed (0.5)(0.1)
U.S.(1.0)(0.3)
International0.00.0
All Other Acquisitions and Divestitures0.00.20.00.1
 U.S. 0.10.2(0.2)0.1
 International 0.00.10.10.1
WW Adjusted Operational6.4 %(2.3)%4.4 %0.8 %
 U.S. 11.0 %(0.4)%5.9 %2.7 %
 International 3.2 %(4.4)%3.0 %(1.0)%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
TWELVE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical MedTech Total
 WW As Reported (0.5)%1.7 %1.4 %1.3 %
 U.S. 1.3 %2.3 %5.4 %3.0 %
 International (1.9)%1.0 %(2.3)%(0.6)%
 WW Currency (4.1)(5.0)(4.8)(4.8)
 U.S. ————
 International (7.2)(10.9)(9.2)(9.7)
 WW Operational 3.6 %6.7 %6.2 %6.1 %
 U.S. 1.3 %2.3 %5.4 %3.0 %
 International 5.3 %11.9 %6.9 %9.1 %
All Other Acquisitions and Divestitures0.30.1(0.1)0.1
 U.S. 0.20.2(0.4)0.0
 International 0.50.10.10.2
WW Adjusted Operational3.9 %6.8 %6.1 %6.2 %
 U.S. 1.5 %2.5 %5.0 %3.0 %
 International 5.8 %12.0 %7.0 %9.3 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$75463318.9 %18.9 %— %
Intl8158110.6 9.6 (9.0)
WW1,5691,4448.6 13.7 (5.1)
SKIN HEALTH / BEAUTY
US5735386.5 6.5 — 
Intl515546(5.6)4.4 (10.0)
WW1,088 1,0840.4 5.4 (5.0)
ORAL CARE
US1641593.3 3.3 — 
Intl207246(16.0)(8.1)(7.9)
WW370 405 (8.4)(3.7)(4.7)
BABY CARE
US93903.4 3.4 — 
Intl264309(14.6)(7.4)(7.2)
WW356 399 (10.6)(5.0)(5.6)
WOMEN'S HEALTH
US4415.6 15.6 — 
Intl217230(5.7)4.4 (10.1)
WW220233(5.5)4.6 (10.1)
WOUND CARE / OTHER
US1091063.3 3.3 — 
Intl5457(7.5)2.9 (10.4)
WW163164(0.5)3.1 (3.6)
TOTAL CONSUMER HEALTH
US1,696 1,529 10.9 10.9 — 
Intl2,071 2,199 (5.8)3.2 (9.0)
WW$3,767 3,728 1.0 %6.4 %(5.4)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,8052,912(3.6)%(3.6)%— %
Intl1,3121,443(9.1)2.1 (11.2)
WW4,1184,355(5.4)(1.8)(3.6)
     REMICADE
     US318511(37.7)(37.7)— 
     US Exports (4)
41395.1 5.1 — 
     Intl116214(45.9)(41.3)(4.6)
     WW475764(37.8)(36.5)(1.3)
     SIMPONI / SIMPONI ARIA
     US280287(2.2)(2.2)— 
     Intl220271(18.6)(7.4)(11.2)
     WW501559(10.2)(4.7)(5.5)
     STELARA
     US1,6211,5425.2 5.2 — 
     Intl764792(3.5)8.1 (11.6)
     WW2,3862,3342.3 6.2 (3.9)
     TREMFYA
     US541 528 2.5 2.5 — 
     Intl211 165 27.5 44.5 (17.0)
     WW752 693 8.5 12.5 (4.0)
     OTHER IMMUNOLOGY
     US3 6 (53.5)(53.5)— 
     Intl0 0 **  *
     WW3 6 (53.3)(53.3)0.0
INFECTIOUS DISEASES
US414614(32.6)(32.6)— 
Intl1,1271,818(38.0)(31.0)(7.0)
WW1,5402,431(36.6)(31.4)(5.2)
     COVID-19 VACCINE
     US0213**— 
     Intl6891,405(50.9)(45.0)(5.9)
     WW6891,619(57.4)(52.2)(5.2)
     EDURANT / rilpivirine
     US9 10 1.21.2— 
     Intl281 220 27.639.2(11.6)
     WW290 230 26.537.6(11.1)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US3983804.74.7— 
     Intl95135(29.5)(20.5)(9.0)
     WW493515(4.3)(1.9)(2.4)
     OTHER INFECTIOUS DISEASES
     US611(47.1)(47.1)— 
     Intl61577.318.0(10.7)
     WW6768(1.6)7.4(9.0)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$9128991.4%1.4%—%
Intl825890(7.2)3.3(10.5)
WW1,7371,789(2.8)2.4(5.2)
     CONCERTA / methylphenidate
     US3755(34.3)(34.3)—
     Intl1311236.520.3(13.8)
     WW168178(6.2)3.4(9.6)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US6786681.81.8—
     Intl329361(8.8)2.7(11.5)
     WW1,0081,029(2.0)2.1(4.1)
     RISPERDAL CONSTA
     US6277(19.4)(19.4)—
     Intl5063(21.5)(9.7)(11.8)
     WW112140(20.4)(15.0)(5.4)
     OTHER NEUROSCIENCE
     US1349935.535.5—
     Intl315342(7.7)0.3(8.0)
     WW4494412.08.2(6.2)
ONCOLOGY
US1,8571,59416.516.5—
Intl2,0692,184(5.3)6.8(12.1)
WW3,9273,7783.910.9(7.0)
     DARZALEX
     US1,139 867 31.431.4—
     Intl944 778 21.336.7(15.4)
     WW2,083 1,645 26.633.9(7.3)
     ERLEADA
     US275 235 17.217.2—
     Intl266 149 78.097.8(19.8)
     WW541 384 40.948.6(7.7)
     IMBRUVICA
     US318 436 (27.0)(27.0)—
     Intl547 626 (12.5)(2.0)(10.5)
     WW866 1,062 (18.5)(12.3)(6.2)
     ZYTIGA / abiraterone acetate
     US2023 (14.3)(14.3)—
     Intl250525(52.4)(44.8)(7.6)
     WW270548(50.8)(43.6)(7.2)
     OTHER ONCOLOGY
     US106 34 **—
     Intl63106(41.1)(33.1)(8.0)
     WW16814020.626.7(6.1)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$610 587 3.9 %3.9 %— %
Intl261 264 (1.3)13.5 (14.8)
WW870 851 2.3 6.9 (4.6)
     OPSUMIT
     US305 286 7.0 7.0 — 
     Intl156 162 (3.7)11.0 (14.7)
     WW461 448 3.1 8.4 (5.3)
     UPTRAVI
     US280 264 6.3 6.3 — 
     Intl56 46 20.4 33.3 (12.9)
     WW336 310 8.4 10.3 (1.9)
     OTHER PULMONARY HYPERTENSION
     US24 38 (35.5)(35.5)— 
     Intl48 56 (12.2)4.4 (16.6)
     WW73 94 (21.7)(11.8)(9.9)
CARDIOVASCULAR / METABOLISM / OTHER
US776813(4.4)(4.4)— 
Intl194200(3.4)5.7 (9.1)
WW9711,013(4.2)(2.4)(1.8)
     XARELTO
     US667 644 3.4 3.4 — 
     Intl— — — — — 
     WW667 644 3.4 3.4 — 
     INVOKANA / INVOKAMET
     US29 59 (51.3)(51.3)— 
     Intl62 60 2.3 11.2 (8.9)
     WW91 120 (24.1)(19.6)(4.5)
     OTHER
     US81 110 (25.7)(25.7)— 
     Intl132 140 (5.9)3.3 (9.2)
     WW213 250 (14.6)(9.4)(5.2)
TOTAL PHARMACEUTICAL
US7,3757,418(0.6)(0.6)— 
Intl5,7886,799(14.9)(4.5)(10.4)
WW$13,16314,217(7.4)%(2.5)%(4.9)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5)
INTERVENTIONAL SOLUTIONS
US$603 483 24.9 %24.9 %— %
Intl495 536(7.6)6.2 (13.8)
WW1,098 1,0197.8 15.1 (7.3)
ORTHOPAEDICS
US1,385 1,305 6.1 6.1 — 
Intl763 851 (10.4)0.8 (11.2)
WW2,148 2,155 (0.4)4.0 (4.4)
     HIPS
     US250 227 9.7 9.7 — 
     Intl135 151 (10.4)0.4 (10.8)
     WW385 378 1.7 6.0 (4.3)
     KNEES
     US231 208 11.8 11.8 — 
     Intl122 135 (9.5)1.2 (10.7)
     WW354 342 3.4 7.6 (4.2)
     TRAUMA
     US470 467 0.7 0.7 — 
     Intl240 261 (7.9)3.5 (11.4)
     WW710 728 (2.4)1.7 (4.1)
     SPINE, SPORTS & OTHER
     US434 403 7.5 7.5 — 
     Intl265 304 (12.9)(1.5)(11.4)
     WW699 708 (1.3)3.6 (4.9)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5) (Continued)
SURGERY
US$1,000 986 1.5 %1.5 %— %
Intl1,383 1,527 (9.4)1.4 (10.8)
WW2,384 2,513 (5.1)1.4 (6.5)
     ADVANCED
US456 457 (0.2)(0.2)— 
Intl653 735 (11.1)(0.4)(10.7)
WW1,109 1,192 (7.0)(0.3)(6.7)
     GENERAL
US544 528 3.1 3.1 — 
Intl731 793 (7.8)3.0 (10.8)
WW1,275 1,321 (3.5)3.0 (6.5)
VISION
US456 443 3.1 3.1 — 
Intl689 728 (5.4)5.9 (11.3)
WW1,145 1,171 (2.2)4.8 (7.0)
     CONTACT LENSES / OTHER
US343 316 8.6 8.6 — 
Intl489 518 (5.6)7.2 (12.8)
WW831 833 (0.2)7.7 (7.9)
     SURGICAL
US113 126 (10.7)(10.7)— 
Intl200 211 (5.0)2.9 (7.9)
WW314 338 (7.1)(2.2)(4.9)
TOTAL MEDTECH
US3,445 3,216 7.1 7.1 — 
Intl3,331 3,643 (8.6)2.9 (11.5)
WW$6,776 6,859 (1.2)%4.9 %(6.1)%
See footnotes at end of schedule








Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$2,7822,5947.3 %7.3 %— %
Intl3,2493,0347.1 14.5 (7.4)
WW6,0315,6277.2 11.2 (4.0)
SKIN HEALTH / BEAUTY
US2,3372,400(2.6)(2.6)— 
Intl2,0152,141(5.9)2.2 (8.1)
WW4,352 4,541(4.2)(0.4)(3.8)
ORAL CARE
US635637(0.3)(0.3)— 
Intl8711,008(13.6)(7.4)(6.2)
WW1,505 1,645 (8.5)(4.7)(3.8)
BABY CARE
US357378(5.5)(5.5)— 
Intl1,1041,188(7.1)(1.4)(5.7)
WW1,461 1,566 (6.7)(2.4)(4.3)
WOMEN'S HEALTH
US13131.7 1.7 — 
Intl891905(1.5)7.1 (8.6)
WW904917(1.5)7.0 (8.5)
WOUND CARE / OTHER
US475495(4.0)(4.0)— 
Intl224243(8.0)(3.4)(4.6)
WW700739(5.3)(3.8)(1.5)
TOTAL CONSUMER HEALTH
US6,599 6,516 1.3 1.3 — 
Intl8,354 8,519 (1.9)5.3 (7.2)
WW$14,953 15,035 (0.5)%3.6 %(4.1)%
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$11,03610,8431.8 %1.8 %— %
Intl5,8995,907(0.1)10.3 (10.4)
WW16,93516,7501.1 4.8 (3.7)
     REMICADE
     US1,4172,019(29.8)(29.8)— 
     US Exports (4)
204236(13.6)(13.6)— 
     Intl722935(22.8)(18.7)(4.1)
     WW2,3433,190(26.6)(25.3)(1.3)
     SIMPONI / SIMPONI ARIA
     US1,1661,1273.5 3.5 — 
     Intl1,0171,148(11.4)(1.4)(10.0)
     WW2,1842,276(4.0)1.0 (5.0)
     STELARA
     US6,3885,9387.6 7.6 — 
     Intl3,3353,1964.4 15.7 (11.3)
     WW9,7239,1346.5 10.4 (3.9)
     TREMFYA
     US1,844 1,503 22.7 22.7 — 
     Intl824 624 32.0 47.8 (15.8)
     WW2,668 2,127 25.4 30.1 (4.7)
     OTHER IMMUNOLOGY
     US17 21 (18.4)(18.4)— 
     Intl03 ***
     WW17 24 (28.2)(28.2)0.0
INFECTIOUS DISEASES
US1,6802,249(25.3)(25.3)— 
Intl3,7693,5765.4 17.3 (11.9)
WW5,4495,825(6.5)0.8 (7.3)
     COVID-19 VACCINE
     US120634(81.1)(81.1)— 
     Intl2,0591,75117.632.1(14.5)
     WW2,1792,385(8.6)2.0(10.6)
     EDURANT / rilpivirine
     US36 41 (10.8)(10.8)— 
     Intl972 953 2.0 12.7 (10.7)
     WW1,008 994 1.5 11.8 (10.3)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,4941,508(1.0)(1.0)— 
     Intl449575(21.9)(13.4)(8.5)
     WW1,9432,083(6.7)(4.4)(2.3)
     OTHER INFECTIOUS DISEASES
     US3066(55.5)(55.5)— 
     Intl289297(2.6)3.6 (6.2)
     WW318363(12.3)(7.2)(5.1)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$3,5703,3476.7 %6.7 %— %
Intl3,3233,641(8.7)0.4 (9.1)
WW6,8936,988(1.4)3.4 (4.8)
     CONCERTA / methylphenidate
     US151172(12.5)(12.5)—
     Intl493495(0.4)9.9(10.3)
     WW644667(3.5)4.1(7.6)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US2,7142,5506.5 6.5 —
     Intl1,4261,472 (3.1)7.8 (10.9)
     WW4,1404,0223.0 6.9 (3.9)
     RISPERDAL CONSTA
     US257287(10.4)(10.4)—
     Intl228305(25.3)(15.5)(9.8)
     WW485592(18.1)(13.0)(5.1)
     OTHER NEUROSCIENCE
     US44733832.432.4—
     Intl1,1761,368(14.1)(7.5)(6.6)
     WW1,6231,706(4.9)0.4(5.3)
ONCOLOGY
US6,9305,95816.316.3—
Intl9,052 8,590 5.417.3(11.9)
WW15,98314,5489.916.9(7.0)
     DARZALEX
     US4,210 3,169 32.832.8—
     Intl3,767 2,854 32.047.0(15.0)
     WW7,977 6,023 32.439.5(7.1)
     ERLEADA
     US968 813 19.219.2—
     Intl913 478 ***
     WW1,881 1,291 45.753.0(7.3)
     IMBRUVICA
     US1,390 1,747 (20.4)(20.4)—
     Intl2,394 2,622 (8.7)1.0(9.7)
     WW3,784 4,369 (13.4)(7.6)(5.8)
     ZYTIGA / abiraterone acetate
     US74 119 (37.8)(37.8)—
     Intl1,6962,178(22.1)(12.3)(9.8)
     WW1,7702,297(22.9)(13.6)(9.3)
     OTHER ONCOLOGY
     US289 110 **—
     Intl283458(38.3)(31.6)(6.7)
     WW5715680.66.0(5.4)
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$2,346 2,365 (0.8)%(0.8)%— %
Intl1,071 1,085 (1.3)11.2 (12.5)
WW3,417 3,450 (1.0)3.0 (4.0)
     OPSUMIT
     US1,132 1,147 (1.3)(1.3)— 
     Intl651 672 (3.2)9.3 (12.5)
     WW1,783 1,819 (2.0)2.6 (4.6)
     UPTRAVI
     US1,104 1,056 4.5 4.5 — 
     Intl218 181 20.4 32.4 (12.0)
     WW1,322 1,237 6.9 8.6 (1.7)
     OTHER PULMONARY HYPERTENSION
     US110 163 (32.3)(32.3)— 
     Intl202 232 (12.8)0.3 (13.1)
     WW313 395 (20.8)(13.1)(7.7)
CARDIOVASCULAR / METABOLISM / OTHER
US3,0423,192(4.7)(4.7)— 
Intl845927(8.9)(1.7)(7.2)
WW3,8874,119(5.6)(4.0)(1.6)
     XARELTO
US2,473 2,438 1.4 1.4 — 
Intl— — — — — 
WW2,473 2,438 1.4 1.4 — 
     INVOKANA / INVOKAMET
US193 308 (37.4)(37.4)— 
Intl255 254 0.1 7.3 (7.2)
WW448 563 (20.4)(17.2)(3.2)
     OTHER
US376 446 (15.5)(15.5)— 
Intl590 673 (12.3)(5.1)(7.2)
WW966 1,119 (13.6)(9.3)(4.3)
TOTAL PHARMACEUTICAL
US28,60427,9542.3 2.3 — 
Intl23,95923,7261.0 11.9 (10.9)
WW$52,56351,6801.7 %6.7 %(5.0)%
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5)
INTERVENTIONAL SOLUTIONS
US$2,169 1,836 18.2 %18.2 %— %
Intl2,1312,135(0.2)9.9 (10.1)
WW4,3003,9718.3 13.7 (5.4)
ORTHOPAEDICS
US5,321 5,126 3.8 3.8 — 
Intl3,267 3,462 (5.6)3.4 (9.0)
WW8,587 8,588 0.03.7 (3.7)
     HIPS
     US943 878 7.3 7.3 — 
     Intl571 602 (5.1)3.6 (8.7)
     WW1,514 1,480 2.3 5.8 (3.5)
     KNEES
     US851 787 8.2 8.2 — 
     Intl508 538 (5.7)3.1 (8.8)
     WW1,359 1,325 2.6 6.1 (3.5)
     TRAUMA
     US1,882 1,819 3.5 3.5 — 
     Intl989 1,066 (7.2)2.6 (9.8)
     WW2,871 2,885 (0.5)3.1 (3.6)
     SPINE, SPORTS & OTHER
     US1,645 1,642 0.2 0.2 — 
     Intl1,198 1,256 (4.6)4.3 (8.9)
     WW2,843 2,898 (1.9)1.9 (3.8)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2)(3)(5) (Continued)
SURGERY
US$3,897 3,867 0.8 %0.8 %— %
Intl5,793 5,945 (2.6)5.7 (8.3)
WW9,690 9,812 (1.2)3.8 (5.0)
     ADVANCED
US1,784 1,761 1.3 1.3 — 
Intl2,785 2,861 (2.6)5.3 (7.9)
WW4,569 4,622 (1.1)3.8 (4.9)
     GENERAL
US2,113 2,105 0.4 0.4 — 
Intl3,008 3,085 (2.5)6.2 (8.7)
WW5,121 5,190 (1.3)3.8 (5.1)
VISION
US1,990 1,857 7.2 7.2 — 
Intl2,859 2,831 1.0 11.1 (10.1)
WW4,849 4,688 3.4 9.5 (6.1)
     CONTACT LENSES / OTHER
US1,522 1,398 8.9 8.9 — 
Intl2,022 2,043 (1.0)10.1 (11.1)
WW3,543 3,440 3.0 9.6 (6.6)
     SURGICAL
US468 459 2.0 2.0 — 
Intl837 788 6.2 13.7 (7.5)
WW1,306 1,248 4.6 9.4 (4.8)
TOTAL MEDTECH
US13,377 12,686 5.4 5.4 — 
Intl14,050 14,374 (2.3)6.9 (9.2)
WW$27,427 27,060 1.4 %6.2 %(4.8)%
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Previously referred to as Medical Devices









Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FOURTH QUARTER
Percent Change
20222021TotalOperationsCurrency
Pharmaceutical
U.S.$7,375  7,418  (0.6)% (0.6) -
International 5,788  6,799  (14.9) (4.5) (10.4)
Worldwide 13,163  14,217  (7.4) (2.5) (4.9)
COVID-19 Vaccine
U.S. 0  213  *  *  -
International 689  1,405  (50.9) (45.0) (5.9)
Worldwide 689  1,619  (57.4) (52.2) (5.2)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 7,375  7,205  2.4  2.4  -
International 5,099  5,394  (5.5) 6.0  (11.5)
Worldwide 12,474  12,599  (1.0) 3.9  (4.9)
Worldwide
U.S. 12,516  12,163  2.9  2.9  -
International 11,190  12,641  (11.5) (1.1) (10.4)
Worldwide 23,706  24,804  (4.4) 0.9  (5.3)
COVID-19 Vaccine
U.S. 0  213  *  *  -
International 689  1,405  (50.9) (45.0) (5.9)
Worldwide 689  1,619  (57.4) (52.2) (5.2)
Worldwide
U.S. 12,516  11,950  4.7  4.7  -
International 10,501  11,236  (6.5) 4.4  (10.9)
Worldwide excluding COVID-19 Vaccine$23,017  23,186  (0.7)% 4.6  (5.3)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful












Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
TWELVE MONTHS
Percent Change
20222021TotalOperationsCurrency
Pharmaceutical
U.S.$28,604  27,954  2.3 % 2.3  -
International 23,959  23,726  1.0  11.9  (10.9)
Worldwide 52,563  51,680  1.7  6.7  (5.0)
COVID-19 Vaccine
U.S. 120  634  (81.1) (81.1) -
International 2,059  1,751  17.6  32.1  (14.5)
Worldwide 2,179  2,385  (8.6) 2.0  (10.6)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 28,484  27,320  4.3  4.3  -
International 21,900  21,975  (0.3) 10.3  (10.6)
Worldwide 50,384  49,295  2.2  6.9  (4.7)
Worldwide
U.S. 48,580  47,156  3.0  3.0  -
International 46,363  46,619  (0.6) 9.1  (9.7)
Worldwide 94,943  93,775  1.3  6.1  (4.8)
COVID-19 Vaccine
U.S. 120  634  (81.1) (81.1) -
International 2,059  1,751  17.6  32.1  (14.5)
Worldwide 2,179  2,385  (8.6) 2.0  (10.6)
Worldwide
U.S. 48,460  46,522  4.2  4.2  -
International 44,304  44,868  (1.3) 8.2  (9.5)
Worldwide excluding COVID-19 Vaccine$92,764  91,390  1.5 % 6.2  (4.7)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful